Taigen Biopharmaceuticals Holdings Ltd (4157) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.070x

Based on the latest financial reports, Taigen Biopharmaceuticals Holdings Ltd (4157) has a cash flow conversion efficiency ratio of -0.070x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-62.73 Million ≈ $-1.98 Million USD) by net assets (NT$892.68 Million ≈ $28.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Taigen Biopharmaceuticals Holdings Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how Taigen Biopharmaceuticals Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Taigen Biopharmaceuticals Holdings Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Taigen Biopharmaceuticals Holdings Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Taigen Biopharmaceuticals Holdings Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
KOSKISEN OYJ EO 1 F:EZ8	0.040x
Taliworks Corporation Bhd KLSE:8524	0.020x
Iron Force Industrial Co Ltd TW:2228	0.080x
Dong Nai Port JSC VN:PDN	0.070x
Caisse régionale de Crédit Agricole Mutuel Atlantique Vendée PA:CRAV	-0.105x
Kwong Lung Enterprise Co Ltd TWO:8916	0.073x
TriSalus Life Sciences Inc. NASDAQ:TLSI	0.139x
Acsion Ltd JSE:ACS	0.034x

Annual Cash Flow Conversion Efficiency for Taigen Biopharmaceuticals Holdings Ltd (2010–2024)

The table below shows the annual cash flow conversion efficiency of Taigen Biopharmaceuticals Holdings Ltd from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see 4157 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$1.08 Billion ≈ $34.10 Million	NT$-173.09 Million ≈ $-5.45 Million	-0.160x	-962.72%
2023-12-31	NT$1.12 Billion ≈ $35.25 Million	NT$20.74 Million ≈ $653.46K	0.019x	+184.54%
2022-12-31	NT$970.03 Million ≈ $30.56 Million	NT$-21.27 Million ≈ $-670.09K	-0.022x	-104.37%
2021-12-31	NT$1.25 Billion ≈ $39.50 Million	NT$629.07 Million ≈ $19.82 Million	0.502x	+191.65%
2020-12-31	NT$442.18 Million ≈ $13.93 Million	NT$-242.10 Million ≈ $-7.63 Million	-0.548x	-30.30%
2019-12-31	NT$815.18 Million ≈ $25.68 Million	NT$-342.52 Million ≈ $-10.79 Million	-0.420x	-80.21%
2018-12-31	NT$1.09 Billion ≈ $34.45 Million	NT$-254.93 Million ≈ $-8.03 Million	-0.233x	-24.43%
2017-12-31	NT$1.42 Billion ≈ $44.88 Million	NT$-266.93 Million ≈ $-8.41 Million	-0.187x	+17.16%
2016-12-31	NT$675.62 Million ≈ $21.29 Million	NT$-152.83 Million ≈ $-4.82 Million	-0.226x	+83.14%
2015-12-31	NT$441.60 Million ≈ $13.91 Million	NT$-592.56 Million ≈ $-18.67 Million	-1.342x	-111.73%
2014-12-31	NT$852.14 Million ≈ $26.85 Million	NT$-540.03 Million ≈ $-17.01 Million	-0.634x	+78.74%
2013-12-31	NT$153.77 Million ≈ $4.84 Million	NT$-458.46 Million ≈ $-14.44 Million	-2.981x	-686.28%
2012-12-31	NT$372.80 Million ≈ $11.75 Million	NT$-141.36 Million ≈ $-4.45 Million	-0.379x	+48.69%
2011-12-31	NT$513.21 Million ≈ $16.17 Million	NT$-379.23 Million ≈ $-11.95 Million	-0.739x	-1713.58%
2010-12-31	NT$-4.29 Billion ≈ $-135.14 Million	NT$-196.43 Million ≈ $-6.19 Million	0.046x	--

About Taigen Biopharmaceuticals Holdings Ltd

TWO:4157 Taiwan Biotechnology

Market Cap

$222.47 Million

NT$7.06 Billion TWD

Market Cap Rank

#16155 Global

#761 in Taiwan

Share Price

NT$9.92

Change (1 day)

-0.80%

52-Week Range

NT$7.52 - NT$15.60

All Time High

NT$37.39